Drug Profile
AZD 8529
Alternative Names: AZD-8529Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Neuropsychotherapeutics; Small molecules
- Mechanism of Action Glutamate modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Schizophrenia
Most Recent Events
- 17 Mar 2015 National Institute on Drug Abuse plans a phase II trial for Smoking withdrawal in USA (NCT02401022)
- 03 May 2011 AstraZeneca completes its phase 0 trial in healthy volunteers in the US [completion after discontinuation] (NCT00985933)
- 09 Mar 2011 AstraZeneca completes enrolment in its phase 0 trial in healthy volunteers in the US (NCT00985933)